{"id":5790,"date":"2024-09-30T07:55:19","date_gmt":"2024-09-30T12:55:19","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5790"},"modified":"2025-06-27T10:42:26","modified_gmt":"2025-06-27T15:42:26","slug":"nanoscope-therapeutics-licenses-optogenetic-catch-technology","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2024\/09\/30\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\/","title":{"rendered":"Nanoscope Therapeutics obtiene la licencia de la tecnolog\u00eda optogen\u00e9tica CatCh"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"5790\" class=\"elementor elementor-5790\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-47199a7a elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"47199a7a\" data-element_type=\"section\" data-e-type=\"section\">\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-3ac0e3b2\" data-id=\"3ac0e3b2\" data-element_type=\"column\" data-e-type=\"column\">\r\n\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-3b8ffa67 elementor-widget elementor-widget-text-editor\" data-id=\"3b8ffa67\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<strong><i>La tecnolog\u00eda innovadora incorporada en la terapia g\u00e9nica de Nanoscope ofrece esperanza para restaurar la visi\u00f3n en casos de discapacidades visuales de origen gen\u00e9tico.<\/i><\/strong><\/p>\n\n\n<span class=\"legendSpanClass\"><span class=\"xn-location\">DALLAS<\/span><\/span>,\u00a0<span class=\"legendSpanClass\"><span class=\"xn-chron\">30 de septiembre de 2024<\/span><\/span> \u2014\u00a0<a href=\"http:\/\/nanostherapeutics.com\/es\/\" target=\"_blank\" rel=\"nofollow noopener\">Nanoscopio Therapeutics Inc.<\/a>, una empresa de biotecnolog\u00eda en fase cl\u00ednica que desarrolla terapias gen\u00e9ticas para enfermedades hereditarias de la retina (ERH) y atrofia geogr\u00e1fica secundaria a la degeneraci\u00f3n macular, anunci\u00f3 hoy que la empresa ha adquirido una licencia para la tecnolog\u00eda CatCh de Max Planck Innovation, la organizaci\u00f3n de transferencia de tecnolog\u00eda de la Sociedad Max Planck. Bas\u00e1ndose en los resultados de la investigaci\u00f3n del Instituto Max Planck de Biof\u00edsica y en el trabajo pionero del profesor.\u00a0<span class=\"xn-person\">Ernesto Bamberg<\/span>\u00a0En el campo de la optogen\u00e9tica, esta tecnolog\u00eda patentada mejora la sensibilidad a la luz de una opsina multicaracter\u00edstica (MCO-010, un complejo de fusi\u00f3n de tres prote\u00ednas que incluye CatCh) desarrollada por Nanoscope como terapia g\u00e9nica para restaurar la visi\u00f3n en pacientes que sufren deficiencias visuales de origen gen\u00e9tico. La innovadora plataforma MCO de Nanoscope es el primer enfoque optogen\u00e9tico que combina m\u00faltiples componentes sensibles a la luz, cuya suma produce una prote\u00edna de fusi\u00f3n que es sensible en todo el espectro visible a niveles de luz ambiental con una cin\u00e9tica r\u00e1pida. Nanoscope ya ha completado con \u00e9xito varios estudios cl\u00ednicos sobre MCO-010 para las dos principales enfermedades degenerativas hereditarias de la retina: retinosis pigmentaria (RP) y enfermedad de Stargardt. La compa\u00f1\u00eda ahora planea buscar la aprobaci\u00f3n para la terapia y expandirse a indicaciones terap\u00e9uticas m\u00e1s amplias. &quot;Estamos entusiasmados de ver los beneficios mejorados de la plataforma MCO, que incorpora la tecnolog\u00eda CatCh del Instituto Max Planck de Biof\u00edsica, y ofrece una nueva esperanza para restaurar la visi\u00f3n en aquellos que sufren afecciones degenerativas graves de la retina&quot;, dijo el Dr.\u00a0<span class=\"xn-person\">Samarendra Mohanty<\/span>, Cofundador y Presidente de Nanoscope Therapeutics. \u201cNuestro acuerdo con Max Planck Innovation nos permite transformar descubrimientos cient\u00edficos revolucionarios en soluciones terap\u00e9uticas eficaces. Con la administraci\u00f3n viral eficiente de la prote\u00edna de fusi\u00f3n MCO-010 no mam\u00edfera bioingenierizada m\u00e1s compleja para tratar afecciones retinianas degenerativas graves causadas por muchas mutaciones gen\u00e9ticas diferentes, estamos a punto de tratar a pacientes con grandes necesidades no cubiertas y mejorar de forma sostenible su calidad de vida\u201d. La Dra. Mareike G\u00f6ritz, gerente de Patentes y Licencias en Max Planck Innovation, agreg\u00f3: \u201cLas propiedades avanzadas de CatCh en combinaci\u00f3n con la tecnolog\u00eda patentada de Nanoscope hacen de este un enfoque muy prometedor para el tratamiento de terapia g\u00e9nica de las deficiencias visuales relacionadas con la retinitis. Estamos entusiasmados por seguir el desarrollo y estar\u00edamos encantados si los pacientes finalmente se beneficiaran de este enfoque innovador\u201d. La ceguera y las deficiencias visuales causadas por enfermedades oculares gen\u00e9ticas como la retinosis pigmentaria, la enfermedad de Stargardt y la degeneraci\u00f3n macular relacionada con la edad representan un desaf\u00edo m\u00e9dico significativo en todo el mundo. Estas enfermedades suelen provocar una p\u00e9rdida progresiva de la visi\u00f3n y afectan considerablemente la calidad de vida de quienes las padecen. Dado que las opciones de tratamiento actuales son limitadas, enfoques innovadores como la plataforma MCO ofrecen ahora una nueva esperanza. Gracias a su capacidad para restaurar parcialmente la visi\u00f3n mediante terapia g\u00e9nica, la plataforma tecnol\u00f3gica de Nanoscope podr\u00eda representar un avance significativo en el tratamiento de estas graves enfermedades oculares.\n\n<b>Aplicaci\u00f3n terap\u00e9utica y pruebas cl\u00ednicas<\/b>\n\nLa tecnolog\u00eda CatCh, ahora licenciada, ha sido integrada por Nanoscope Therapeutics como una de las tres subunidades de la prote\u00edna de fusi\u00f3n MCO-010, cada una de las cuales aporta propiedades complementarias activadas por la luz, que en conjunto dan como resultado un tratamiento con el potencial de restaurar la visi\u00f3n en entornos cotidianos. El novedoso enfoque terap\u00e9utico MCO-010 de Nanoscope ha sido probado con \u00e9xito en m\u00faltiples estudios cl\u00ednicos para la retinosis pigmentaria (RP) y la enfermedad de Stargardt. Adem\u00e1s, la plataforma MCO ya se est\u00e1 probando y ha demostrado ser eficaz en primates no humanos con atrofias geogr\u00e1ficas (AG) secundarias a la degeneraci\u00f3n macular asociada a la edad (DMAE) avanzada. El desarrollo posterior y la v\u00eda de aprobaci\u00f3n de MCO-010 se est\u00e1n revisando intensivamente. Nanoscope Therapeutics aspira a obtener la aprobaci\u00f3n y est\u00e1 en conversaciones con la Administraci\u00f3n de Alimentos y Medicamentos de los Estados Unidos (FDA) para explorar posibles v\u00edas aceleradas para su comercializaci\u00f3n. Estos esfuerzos podr\u00edan ayudar a que la terapia innovadora est\u00e9 disponible m\u00e1s r\u00e1pidamente para los pacientes que necesitan urgentemente nuevas opciones de tratamiento. La tecnolog\u00eda CatCh (canalrodopsina transportadora de calcio) fue desarrollada por el Prof.\u00a0<span class=\"xn-person\">Ernesto Bamberg<\/span>, uno de los pioneros en el campo de la optogen\u00e9tica, y sus colegas del Instituto Max Planck de Biof\u00edsica. CatCh, un mutante de la canalrodopsina-2 con propiedades mejoradas, ofrece ventajas significativas como una cin\u00e9tica m\u00e1s r\u00e1pida y una mayor sensibilidad a la luz azul.\n\n<b>Acerca de Nanoscope Therapeutics Inc.<\/b>\n\nNanoscope Therapeutics es una empresa biofarmac\u00e9utica en fase cl\u00ednica que desarrolla terapias gen\u00e9ticas independientes de las mutaciones para tratar enfermedades degenerativas de la retina que causan deterioro de la visi\u00f3n y ceguera, para las que hasta la fecha no existe cura. La empresa\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&l=en&o=4https:\/\/nanostherapeutics.com\/2024\/03\/26\/nanoscope-therapeutics-announces-top-line-results-from-ph2-trial-of-mco-010-for-retinitis-pigmentosa\/265966-1&h=3390199264&u=https%3A%2F%2Fnanostherapeutics.com%2F2024%2F03%2F26%2Fnanoscope-therapeutics-announces-top-line-results-from-ph2-trial-of-mco-010-for-retinitis-pigmentosa%2F&a=recently+announced+the+100-week+data+from\" target=\"_blank\" rel=\"nofollow noopener\">anunci\u00f3 recientemente los datos de 100 semanas de<\/a>\u00a0el ensayo cl\u00ednico RESTORE de fase 2b\/3, multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo en EE. UU. para la retinitis pigmentosa (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04945772?tab=history&a=4\" target=\"_blank\" rel=\"nofollow noopener\">NCT04945772<\/a>). La compa\u00f1\u00eda tambi\u00e9n complet\u00f3 recientemente el ensayo de fase 2 STARLIGHT de la terapia MCO-010 en pacientes con enfermedad de Stargardt (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05417126?tab=history&a=5\" target=\"_blank\" rel=\"nofollow noopener\">NCT05417126<\/a>). El MCO-010 ha recibido designaciones de v\u00eda r\u00e1pida de la FDA y de medicamento hu\u00e9rfano de la FDA tanto para la RP como para la enfermedad de Stargardt. Los activos precl\u00ednicos incluyen la terapia g\u00e9nica MCO-020 administrada con l\u00e1ser no viral para la atrofia genitourinaria secundaria a la DMAE.\n\n<b>Contacto de inversores:<\/b><br class=\"dnr\" \/>Socios Argot<br class=\"dnr\" \/>(212) 600-1902<br class=\"dnr\" \/><a href=\"mailto:PR@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a>\n\nFUENTE Terap\u00e9utica del Nanoscopio\n\n<\/div>\n<\/div>\n<\/section><\/article>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Innovative technology incorporated in Nanoscope\u2019s gene therapy offers hope for restoring vision in genetically caused visual impairments DALLAS,\u00a0Sept. 30, 2024 \u2014\u00a0Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases (IRDs) and geographic atrophy secondary to macular degeneration, today announced that the company has acquired a license for the CatCh technology [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":5792,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5790","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics Licenses Optogenetic CatCh Technology - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2024\/09\/30\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Licenses Optogenetic CatCh Technology - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2024\/09\/30\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2024-09-30T12:55:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-27T15:42:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_LI_CatCH_PR.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"627\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_LI_CatCH_PR.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/30\\\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/30\\\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics Licenses Optogenetic CatCh Technology\",\"datePublished\":\"2024-09-30T12:55:19+00:00\",\"dateModified\":\"2025-06-27T15:42:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/30\\\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\\\/\"},\"wordCount\":793,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/30\\\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/NSCOPE_LI_CatCH_PR.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/30\\\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/30\\\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\\\/\",\"name\":\"Nanoscope Therapeutics Licenses Optogenetic CatCh Technology - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/30\\\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/30\\\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/NSCOPE_LI_CatCH_PR.jpg\",\"datePublished\":\"2024-09-30T12:55:19+00:00\",\"dateModified\":\"2025-06-27T15:42:26+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/30\\\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/30\\\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/30\\\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/NSCOPE_LI_CatCH_PR.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/NSCOPE_LI_CatCH_PR.jpg\",\"width\":1200,\"height\":627},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/30\\\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Licenses Optogenetic CatCh Technology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics obtiene la licencia de la tecnolog\u00eda optogen\u00e9tica CatCh - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2024\/09\/30\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics Licenses Optogenetic CatCh Technology - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2024\/09\/30\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2024-09-30T12:55:19+00:00","article_modified_time":"2025-06-27T15:42:26+00:00","og_image":[{"width":1200,"height":627,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_LI_CatCH_PR.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_LI_CatCH_PR.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"4 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2024\/09\/30\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2024\/09\/30\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics Licenses Optogenetic CatCh Technology","datePublished":"2024-09-30T12:55:19+00:00","dateModified":"2025-06-27T15:42:26+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/09\/30\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\/"},"wordCount":793,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/09\/30\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_LI_CatCH_PR.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2024\/09\/30\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\/","url":"https:\/\/nanostherapeutics.com\/2024\/09\/30\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\/","name":"Nanoscope Therapeutics obtiene la licencia de la tecnolog\u00eda optogen\u00e9tica CatCh - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/09\/30\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/09\/30\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_LI_CatCH_PR.jpg","datePublished":"2024-09-30T12:55:19+00:00","dateModified":"2025-06-27T15:42:26+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2024\/09\/30\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2024\/09\/30\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2024\/09\/30\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_LI_CatCH_PR.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_LI_CatCH_PR.jpg","width":1200,"height":627},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2024\/09\/30\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Licenses Optogenetic CatCh Technology"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5790","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=5790"}],"version-history":[{"count":5,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5790\/revisions"}],"predecessor-version":[{"id":9023,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5790\/revisions\/9023"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/5792"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=5790"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=5790"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=5790"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}